Related Experiment Videos
Clopidogrel: secondary prevention of vascular ischaemic events
J Misson1, W Clark, M J Kendall
1Department of Medicines Management, Keele University, UK.
Insights
Clopidogrel offers a marginal benefit over aspirin for preventing ischemic vascular events in high-risk patients with atherosclerotic disease. It serves as an alternative for those intolerant to aspirin in secondary prevention strategies.
Area of Science:
- Cardiology
- Vascular Medicine
- Pharmacology
Background:
- Atherosclerotic disease is a leading cause of premature mortality.
- Antiplatelet therapy, particularly aspirin, reduces subsequent event risk by approximately 20% in these patients.
- Identifying effective alternatives to aspirin for secondary prevention is crucial.
Purpose of the Study:
- To evaluate the efficacy of clopidogrel compared to aspirin in preventing vascular ischemic events.
- To determine clopidogrel's role as an alternative antiplatelet therapy for high-risk patients.
Main Methods:
- A comprehensive literature search was conducted using MEDLINE, EMBASE, and the Cochrane library.
- The search utilized the keyword 'clopidogrel'.
- One relevant randomized controlled trial was identified and analyzed.
Main Results:
- Clopidogrel demonstrated a marginal benefit over aspirin in preventing ischemic vascular events.
- This benefit was observed in high-risk patient populations.
- The study confirmed clopidogrel's potential as an alternative treatment.
Conclusions:
- Clopidogrel is a viable alternative for secondary prevention in patients with atherosclerotic disease who cannot tolerate aspirin.
- Further research may explore optimal use in specific high-risk subgroups.
- Evidence supports clopidogrel's role in managing atherosclerotic disease complications.
Abstract:
Atherosclerotic disease is one of the major causes of premature death. In patients with atherosclerotic disease, antiplatelet therapy with aspirin has been shown to decrease the risk of subsequent events by about 20%. In one large randomized controlled study, clopidogrel showed a marginal benefit over aspirin in the prevention of ischaemic vascular events in high-risk patients. Clopidogrel is therefore an alternative in secondary prevention for those patients who are unable to tolerate aspirin. A literature search was performed using MEDLINE, EMBASE, and the Cochrane library, using the keyword 'clopidogrel'. One published randomized, controlled trial was found which evaluated the effects of clopidogrel in the prevention of vascular ischaemic events.